Ampullary stenosis and choledocholithiasis post Roux-En-Y gastric bypass: challenges of biliary access and intervention.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
10 2020
Historique:
received: 21 08 2019
revised: 13 01 2020
accepted: 14 02 2020
pubmed: 29 4 2020
medline: 26 10 2021
entrez: 29 4 2020
Statut: ppublish

Résumé

Ampullary stenosis following Roux-en-Y gastric bypass (RYGB) is increasingly encountered. We describe cases of biliary obstruction from ampullary stenosis and choledocholithiasis to illustrate the associated diagnostic and interventional challenges with this condition. We reviewed medical records of patients with prior RYGB who underwent a biliary access procedure or surgery for non-malignant disease from January 2012-December 2018. We identified 15 patients (4 male, 11 female; mean age 53.7 years) who had RYGB on average 11.7 years (range 1-32) years before diagnosis of biliary obstruction. Fourteen patients reported abdominal pain, 5 had nausea/emesis, 12 had elevated liver function tests, and 6 had ascending cholangitis. Mean common bile duct (CBD) diameter at presentation was 16.9 mm (range 4.0-25.0 mm). Operations included 3 transduodenal ampullectomies (2 with biliary bypass), 2 CBD explorations with stone extraction, 1 laparoscopic cholecystectomy alone, 1 Whipple procedure, 1 balloon enteroscopy with sphincterotomy, and 7 transgastric endoscopic retrograde cholangiopancreatography. All ampulla pathology was benign in patients who underwent resection. At follow-up (mean 15.4 months; range 0.23-44.5 months), 12/15 (80%) reported symptom resolution or improvement. Ampullary stenosis after RYGB presents challenges for diagnostic evaluation and intervention, often requiring multi-disciplinary expertise. The underlying pathology remains to be elucidated.

Sections du résumé

BACKGROUND
Ampullary stenosis following Roux-en-Y gastric bypass (RYGB) is increasingly encountered. We describe cases of biliary obstruction from ampullary stenosis and choledocholithiasis to illustrate the associated diagnostic and interventional challenges with this condition.
METHODS
We reviewed medical records of patients with prior RYGB who underwent a biliary access procedure or surgery for non-malignant disease from January 2012-December 2018.
RESULTS
We identified 15 patients (4 male, 11 female; mean age 53.7 years) who had RYGB on average 11.7 years (range 1-32) years before diagnosis of biliary obstruction. Fourteen patients reported abdominal pain, 5 had nausea/emesis, 12 had elevated liver function tests, and 6 had ascending cholangitis. Mean common bile duct (CBD) diameter at presentation was 16.9 mm (range 4.0-25.0 mm). Operations included 3 transduodenal ampullectomies (2 with biliary bypass), 2 CBD explorations with stone extraction, 1 laparoscopic cholecystectomy alone, 1 Whipple procedure, 1 balloon enteroscopy with sphincterotomy, and 7 transgastric endoscopic retrograde cholangiopancreatography. All ampulla pathology was benign in patients who underwent resection. At follow-up (mean 15.4 months; range 0.23-44.5 months), 12/15 (80%) reported symptom resolution or improvement.
DISCUSSION
Ampullary stenosis after RYGB presents challenges for diagnostic evaluation and intervention, often requiring multi-disciplinary expertise. The underlying pathology remains to be elucidated.

Identifiants

pubmed: 32340857
pii: S1365-182X(20)30054-X
doi: 10.1016/j.hpb.2020.02.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1496-1503

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Andrew D Wisneski (AD)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States.

Jonathan Carter (J)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States.

Eric K Nakakura (EK)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States.

Andrew Posselt (A)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States.

Stanley J Rogers (SJ)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States.

John P Cello (JP)

University of California San Francisco, Department of Medicine, Division of Gastroenterology, 513 Parnassus Avenue, S-357, San Francisco, CA, 94143-0538, United States.

Mustafa Arain (M)

University of California San Francisco, Department of Medicine, Division of Gastroenterology, 513 Parnassus Avenue, S-357, San Francisco, CA, 94143-0538, United States.

Kimberly S Kirkwood (KS)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States.

Kenzo Hirose (K)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States.

Lygia Stewart (L)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States; San Francisco Veterans Affairs Medical Center, Department of Surgery, 4150 Clement Street, Box 112, San Francisco, CA, 94121, United States.

Carlos U Corvera (CU)

University of California San Francisco, Department of Surgery, 513 Parnassus Avenue S-321, San Francisco, CA, 94143-0470, United States; San Francisco Veterans Affairs Medical Center, Department of Surgery, 4150 Clement Street, Box 112, San Francisco, CA, 94121, United States. Electronic address: Carlos.Corvera@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH